Engflag

Novagest with Codeine

Quick links to important sections

Novagest with Codeine

Novagest with Codeine_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Novagest with Codeine

Quick Facts

Property Description
Active Ingredients Codeine, Guaifenesin, Pseudoephedrine
Form Oral Solution (Syrup/Liquid)
Pharmacological Class Antitussive/Expectorant/Decongestant
Common Use Context Symptomatic relief of cough and cold symptoms
Origin Derived (Codeine) and Synthetic (Guaifenesin, Pseudoephedrine)

Novagest with Codeine is a prescription Oral Solution formulated as a fixed-dose combination product designed for the integrated management of concurrent, often severe, upper respiratory tract symptoms. Its inclusion of Codeine, an opioid derivative, requires a medical prescription and places it under controlled substance regulations, a key distinction from most over-the-counter cold medicines.

What Type of Medicine is Novagest with Codeine?

This medicine is categorized as an Antitussive/Expectorant/Decongestant blend, an approach designed for addressing multiple symptoms simultaneously with a single oral dose. The primary antitussive, Codeine, acts on the central nervous system to suppress the persistent cough reflex. Its status as a combination product, typically marketed as a liquid or syrup, is a distinctive feature, positioning it for adult patients seeking relief from a severe, disruptive cough accompanied by congestion.

Composition: The Three Active Ingredients

The formulation consists of three key active pharmaceutical ingredients (APIs): Codeine, Guaifenesin, and Pseudoephedrine, presented within a flavored syrup base. Each component contributes a distinct pharmacological action to the overall relief: Codeine provides centralized cough suppression; Guaifenesin acts as the expectorant; and Pseudoephedrine functions as a systemic decongestant. Guaifenesin works by increasing the volume of secretions in the respiratory tract, thereby helping to thin and facilitate the clearance of viscous mucus. The use of this specific Codeine/Pseudoephedrine combination defines its pharmacological profile.

General Purpose of the Triple-Action Formula

The overall purpose of this triple-action formula is to provide integrated symptomatic relief when a patient is experiencing a cluster of symptoms where single-agent treatment is insufficient. This integrated action aims to minimize the overall burden of symptoms—quieting the cough, thinning the mucus, and clearing the nose—to promote comfort during recovery from a respiratory illness.

Regulatory References

  1. Codeine

What side effects are possible with Novagest with Codeine?

Adverse reaction scope

Key adverse reaction categories: The safety profile is characterized by the opioid effects of the Codeine component and the sympathomimetic effects of Pseudoephedrine, with official categories spanning risks from mild to life-threatening.

Frequency classification:

  • Most Common: Drowsiness, lightheadedness, dizziness, headache, nausea, vomiting, and constipation are frequently reported, predominantly related to the codeine component.
  • Uncommon: Gastrointestinal disturbance, skin rashes, and nervousness are also documented in regulatory sources.

System-organ classes involved: Adverse reactions are documented across several systems, including Nervous System Disorders (e.g., sedation, seizures), Gastrointestinal Disorders (e.g., constipation, potential for Ischaemic colitis), Respiratory, Thoracic & Mediastinal Disorders (e.g., Life-Threatening Respiratory Depression), and Cardiac/Vascular Disorders (e.g., hypertension, severe hypotension).

Serious adverse reactions (as documented in regulatory sources): Life-Threatening Respiratory Depression is a critical, mandated warning. Other serious documented risks include Addiction, Abuse, and Misuse, Neonatal Opioid Withdrawal Syndrome (NOWS), Severe Hypotension, Adrenal Insufficiency, Serotonin Syndrome, and rare cerebrovascular events.

Population-specific safety considerations:

  • Pediatric Patients (Under 12 years): Codeine is not indicated due to the risk of life-threatening respiratory depression. Restrictions also apply to adolescents with certain risk factors.
  • Pregnant/Lactating Patients: Prolonged use during pregnancy is linked to NOWS; use while breastfeeding is contraindicated due to the risk of serious adverse effects in the infant.

Dose- or exposure-related patterns (if explicitly stated): Close monitoring for respiratory depression is specified by regulators as being required at treatment initiation or following a dose increase. Adrenal Insufficiency and Opioid Tolerance/Dependence are risks associated with long-term exposure.

Safety-related restrictions or limitations: The label restricts use in individuals identified as CYP2D6 Ultra-Rapid Metabolizers due to the fatal risk of rapid codeine conversion. Concomitant use with other CNS depressants may result in profound sedation and respiratory depression.

Safety classifications (high-level)

Regulatory basis: Statements are derived from the official regulatory documents of government authorities, such as the FDA and EMA/national agencies.

Context-of-use safety notes (as defined in official documents): Accidental Ingestion, particularly by children, is explicitly documented as a potential cause of a fatal overdose.

Resulting safety structure

  • Life-Threatening Respiratory Depression and the potential for Abuse and Dependence are the central serious risks documented across regulatory labels.
  • The most frequently reported adverse reactions affect the Nervous System and the Gastrointestinal System.
  • Specific populations, including pediatrics and pregnant/lactating individuals, have explicit regulatory safety constraints.

Connection to the overall safety profile (2–4 sentences): The official safety information establishes the drug's risk profile by detailing the expected frequency of common, non-serious reactions alongside the critical documentation of severe adverse reactions associated with the opioid component. This framework explicitly addresses risks tied to specific conditions, such as patient metabolic status, and defines the regulatory limitations for use in vulnerable populations, requiring close observation, especially at treatment initiation.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

This section describes the officially documented clinical manifestations and emergency actions required in the event of an overdose involving Novagest with Codeine (Codeine/Guaifenesin/Pseudoephedrine).

Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations Overdose is characterized by a combination of effects: life-threatening respiratory depression (slow/shallow breathing, long pauses) and CNS depression (extreme sedation, confusion, coma, small pupils, cold/clammy skin) from the opioid component. Cardiovascular risks include low blood pressure, slow heartbeat, seizures, and arrhythmias (fast, irregular heart rate) associated with the pseudoephedrine component.
Population-specific Overdose Notes The product is restricted to use in patients 18 years and older. Older adults and debilitated patients are at a higher risk for developing serious breathing problems, sedation, or confusion. Accidental exposure in children may cause death.
When immediate medical help is required Call 911 (or local emergency number) immediately or contact a Poison Control Center. Seek urgent medical care if the individual collapses, has a seizure, is hard to wake up, or exhibits blue lips/fingernails (cyanosis).
Emergency-response Statements Management includes providing breathing support and administering Naloxone (the specific reversal agent for the opioid component). Hospital monitoring is required, including the measurement of vital signs and an ECG to assess for cardiac complications.

Connection to the Overall Overdose Profile

Regulatory documents define this overdose as a severe medical emergency primarily due to the risk of respiratory failure. The dual nature of the combination product mandates specialized management to address both the life-threatening central nervous system depression, reversible by Naloxone, and the potential cardiovascular excitation.

Therapeutic Uses of Novagest with Codeine

Primary Therapeutic Uses

Novagest with Codeine is a prescription combination medication used to provide relief from specific symptoms associated with common respiratory tract conditions. Its primary therapeutic role centers on addressing cough and certain accompanying cold or allergy symptoms.

The main therapeutic applications for this formulation include:

  • Cough Suppression: The codeine component acts as a cough suppressant (antitussive), working on the central nervous system to decrease the urge to cough. This provides symptomatic relief from persistent coughing.
  • Relief from Cold and Allergy Symptoms: The other active ingredients in this compound typically address symptoms such as nasal congestion, runny nose, sneezing, and watery eyes often linked to the common cold or seasonal allergies. This multi-component action helps to manage the overall discomfort of these conditions. Codeine is used for the management of mild to moderate pain where alternative treatments are inadequate.

Quick Facts

  • Relief of Cough
  • Symptomatic management of cold and allergy symptoms
  • Treatment of mild to moderate pain

Eligibility and Restrictions for Use

Who Can and Cannot Use Novagest with Codeine?

The use of Novagest with Codeine is governed by strict regulatory rules established by health authorities, primarily due to the Codeine component, which is an opioid. The following criteria define who is eligible and who is prohibited from using the medicine.

  • Absolute Contraindications (Must Not Use): Use is strictly prohibited for children under 12 years of age for any indication, and for all women who are breastfeeding. It is also contraindicated for patients known to be CYP2D6 ultra-rapid metabolizers and for any pediatric patient (under 18) following tonsillectomy or adenoidectomy. The medicine must not be taken with or within 14 days of stopping MAOI therapy.

  • Age-Based Eligibility: Only adults 18 years and older are generally eligible for use. Use is not recommended for adolescents (12–18 years) who have existing compromised respiratory function.

  • Comorbidity Restrictions (Use with Caution): Official labeling requires use with extreme caution or restriction in patients with severe hepatic or renal impairment, pre-existing respiratory depression, severe hypertension, or severe coronary artery disease. Caution is also specified for patients with head injury, glaucoma, or diabetes mellitus. These restrictions define the specific population that can safely receive the prescription.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Novagest with Codeine identifies several substances and drug classes that carry significant risk of interaction, primarily due to the opioid (Codeine) and sympathomimetic (Pseudoephedrine) components.

Contraindicated and High-Risk Combinations

Classification Interacting Agents / Conditions Outcome or Constraint
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Risk of severe hypertensive reactions or exaggerated CNS effects; use is prohibited within 14 days of stopping MAOI therapy.
Use Avoided Mixed Agonist/Antagonist Opioid Analgesics Risk of reduced efficacy or precipitated opioid withdrawal.
Clinically Significant CNS Depressants (including Alcohol) Risk of profound sedation, respiratory depression, coma, and death due to additive effects.

Metabolic and Pharmacodynamic Interactions

The Codeine component is a prodrug subject to enzyme metabolism. Regulatory labels specify pharmacokinetic interactions with:

  • CYP2D6 Inhibitors: Co-administration may reduce the formation of the active metabolite, morphine, formally resulting in potential reduced efficacy or opioid withdrawal.
  • Serotonergic Drugs: Pharmacodynamic co-administration with these agents may result in the formal condition of serotonin syndrome.
  • Anticholinergic Drugs: Co-administration may produce an additive anticholinergic effect, posing a risk for conditions such as paralytic ileus.

Additionally, specific populations carry documented interaction considerations, including CYP2D6 Ultra-rapid Metabolizers, who are at risk for elevated morphine exposure and severe respiratory depression.

Mechanism of Action

The formulation Novagest with Codeine influences physiological processes through two distinct mechanistic domains: central nervous system (CNS) modulation and peripheral receptor antagonism.

Modulating the Central Cough Reflex

This domain centers on the opioid component (Codeine) acting as an agonist at the mu (mu) opioid receptors in the brainstem. The mechanism involves the active metabolite binding to these receptors, which inhibits the transmission of signals within the medullary cough center. This modulation of the descending pathways elevates the neural threshold required to trigger the involuntary cough reflex, directly resulting in suppression of the central cough reflex.

Antagonizing Histamine Signaling and Secretion

The second domain involves the antihistamine component (e.g., Chlorpheniramine) which acts as a competitive antagonist at the Histamine H1 receptors. By blocking histamine from binding to these receptors on peripheral tissues and blood vessels, the drug alters signaling dynamics related to secretory responses. This action inhibits the downstream signaling effects of histamine release, such as increasing vascular permeability and stimulating gland secretion, which causes decreased fluid production in the upper respiratory tract.

Dosage and Administration Information

How Novagest with Codeine is Used: Administration Guidelines

This combination oral solution is intended for short-term use only, administered at the lowest effective dosage. This usage protocol ensures appropriate duration and limits unnecessary exposure.

Administration Feature Guideline
Route of Administration The medicine is administered exclusively via oral ingestion of the liquid solution.
Standard Dosing The typical dose for adults is 5 mL to 10 mL. The total consumption is limited and must not exceed 40 mL within a 24-hour period.
Frequency Doses are administered as needed, typically spaced every 6 to 8 hours apart.
Measurement The dose must be measured using a calibrated oral device (syringe or measuring cup) provided with the product. Household utensils are not accurate and must not be used for dispensing.
Timing with Food The solution may be taken with or without food; ingestion with food may be an option to minimize gastric discomfort.

Population-Specific Use and Duration

The use of this codeine-containing syrup is contraindicated in children under 12 years of age. For older adults (65 years and older), a smaller initial dose may be required.

The course of treatment is designed to be short-term. If the condition for which the syrup is taken is unresponsive, or symptoms persist, typically beyond 5 to 7 days, use of the product should be stopped, and the need for continued treatment must be professionally reevaluated.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Novagest with Codeine

Research Evidence for Cough Suppression

Studies of the individual components, the antitussive (Codeine) and expectorant (Guaifenesin), have been conducted using Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies primarily examined how symptoms change over time in adult populations experiencing acute cough, often focusing on outcomes related to episodic or acute changes in the cough reflex.

Research has explored short-term symptom changes, with findings describing patterns observed in the studies. Some systematic reviews of the evidence, however, suggest that findings were mixed regarding the measured changes in cough frequency for Codeine in the acute setting. Long-term effects are not fully established by the existing research, as the follow-up durations were limited to the acute phase of illness.

Research Evidence for Symptomatic Cold and Allergy Relief

Research for the decongestant (Pseudoephedrine) and expectorant (Guaifenesin) components primarily relies on RCTs and studies monitoring symptoms like nasal congestion. The research examined outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort in adults experiencing acute cold or respiratory symptoms.

Trials reported measurements of changes in nasal patency and congestion in studies of Pseudoephedrine and similar decongestants. Evidence contributes to understanding symptom patterns, but comparative evidence is lacking specifically for this full triple combination product versus other similar formulations.

Evidence in Special Populations and Limitations

The Codeine component was studied for its role in managing mild to moderately severe pain in adult patients. However, research has explored the observation that the measured changes for Codeine can vary across individuals due to differences in how patients process the medicine; this is a recognized factor in the available data.

Research highlights that the Codeine component was observed in some studies in children, but due to safety considerations, the product is subject to severe regulatory restrictions, reflecting the limited evidence base for this age group. Limited information is available on how this specific combination product has been evaluated in older adults or in patients with complex pre-existing health conditions (comorbidities).

Frequently Asked Questions (FAQ)

Common questions about Novagest with Codeine (FAQ)

Q: What is the typical timeframe before Novagest with Codeine starts to work?

A: Official information regarding medicines containing Codeine indicates that the active components generally begin to exert their peak effects in the body around one hour after the medication is taken. This timeframe reflects the pharmacokinetics, or how the medicine moves through the body, of the opioid component.

Q: How long does the effect of Novagest with Codeine usually last?

A: The typical duration of the medicine's effect is reflected in the official regulatory guidance for its administration. This guidance advises that doses are typically spaced every 6 to 8 hours apart as needed, aligning with the general therapeutic window documented for the drug.

Q: Is it possible to develop a tolerance to Novagest with Codeine?

A: Official safety information acknowledges that Opioid Tolerance is a documented risk associated with this class of medicine. This risk is primarily linked to repeated use or prolonged exposure. The primary documentation regarding this risk focuses on repeated use or prolonged exposure.

Q: How should Novagest with Codeine be stopped after long-term use?

A: Official documentation describes a process of gradual dose reduction, sometimes called tapering, to minimize withdrawal symptoms in cases of dependence that may arise from long-term use. Abrupt discontinuation is documented as carrying a risk of precipitating withdrawal symptoms.

Q: What precautions apply when Novagest with Codeine is used by older adults?

A: Official documents require caution for use in older adults (65 years and older), who may be more sensitive to the effects of the opioid component. Regulatory guidelines state that a lower starting dose may be needed, and patients in this age group are subject to close monitoring for adverse effects like respiratory depression.

Q: What is the duration of treatment typically recommended for Novagest with Codeine?

A: The medicine is strictly intended for short-term use only, according to official prescribing information. Regulatory guidelines state that if symptoms do not improve or worsen, treatment should typically be stopped after a period of 5 to 7 days, and the need for continued treatment must be professionally reevaluated.

Q: Is Novagest with Codeine available over the counter?

A: No, this medicine is not available over the counter. Due to the presence of Codeine, an opioid, it is categorized by regulatory bodies as a controlled substance and always requires a medical prescription from a licensed practitioner.

Q: Is Novagest with Codeine classified as a controlled substance?

A: Yes, official drug authorities, such as the U.S. Drug Enforcement Administration (DEA), classify this combination product as a controlled substance, often designated as Schedule V. This classification is based on the inclusion of the opioid component, Codeine.

Q: Can Novagest with Codeine cause drowsiness or make you sleepy?

A: Yes, the official safety documentation for the drug lists drowsiness as one of the most common side effects reported by patients. This effect is primarily related to the mechanism of action of the Codeine component on the central nervous system.

Q: What happens if a dose of Novagest with Codeine is missed?

A: Guidance generally advises continuing with the regular dosing schedule if a dose is missed. Taking a double dose to compensate for a missed one is discouraged, and the product information advises against it.

Q: Can Novagest with Codeine affect the ability to drive or operate machinery?

A: Yes, regulatory documents clearly warn that the medicine may impair the mental and physical abilities needed to perform tasks like driving a car or operating machinery. This caution is due to the potential for side effects such as drowsiness, dizziness, and other CNS effects.

Q: Are there any known food interactions with Novagest with Codeine?

A: Official prescribing guidelines state that the liquid solution may be taken with or without food. Taking the medicine with food may be an option for some individuals to help minimize gastric discomfort.

Q: Is Novagest with Codeine the same as a plain codeine product?

A: No, Novagest with Codeine is a fixed-dose combination product containing three distinct active ingredients. In addition to Codeine, it also contains an expectorant (Guaifenesin) and a decongestant (Pseudoephedrine), making it different from a product containing only Codeine.

Q: Are there different strengths or forms of Novagest with Codeine available?

A: Official documents describe the formulation as an Oral Solution (a liquid or syrup) containing a set concentration of its three active ingredients. The existence of other distinct strengths or forms is not typically detailed on the primary product label.

Q: Is it normal to feel slightly dizzy after taking Novagest with Codeine?

A: Official documents classify dizziness and lightheadedness among the most common adverse reactions. This indicates that dizziness is a commonly documented and reported effect of the medication.

Q: Does Novagest with Codeine contain any common allergens like gluten or lactose?

A: Regulatory documents require a full listing of all inactive ingredients (excipients) used in the formulation. Official labeling contains a full list of inactive ingredients. The presence of specific allergens, such as gluten or lactose, is detailed within this official listing.

Q: What is the risk of dependence associated with Novagest with Codeine?

A: Regulatory authorities have issued a Boxed Warning that highlights the risk for addiction, abuse, and misuse with this drug, which can lead to physical dependence. This serious risk is present even when the medication is used exactly as prescribed.

Q: What are the general population demographics studied in the research for Novagest with Codeine?

A: Clinical studies supporting the components of this medicine primarily examined outcomes in adult populations. Regulatory documentation indicates limited data is available specifically regarding the combination product's use in older adults or in patients with complicated, pre-existing health conditions.

Q: Can Novagest with Codeine affect the results of any common medical tests?

A: Official drug documents note that the opioid component has the potential to affect certain bodily functions, which in turn could lead to alterations in the results of some laboratory or diagnostic tests. These effects are documented, for instance, in relation to tests involving the pancreatic and biliary tract systems.

Q: Does Novagest with Codeine interact with common psychiatric medications?

A: Yes, official labels include warnings about potential drug interactions with classes often used for psychiatric conditions. This includes CNS depressants, which can cause profound sedation, and Serotonergic drugs, which pose a risk of Serotonin Syndrome when combined with the opioid component.

Q: Can Novagest with Codeine be taken on an empty stomach?

A: Official guidance states that the medicine may be administered with or without food. It is generally a flexible dosing condition, although taking it with food is sometimes an option to help minimize gastric discomfort.

Q: Are there genetic factors that might affect how Novagest with Codeine works for someone?

A: Yes, regulatory documents specifically warn about the risk for individuals who are CYP2D6 ultra-rapid metabolizers. This genetic difference causes the body to process Codeine too quickly, leading to dangerously high levels of the active drug component in the body.

Q: Does Novagest with Codeine have an anticholinergic effect?

A: Official documents caution that when this drug is co-administered with other anticholinergic agents, it may produce an additive anticholinergic effect. This refers to an increased risk of side effects like dry mouth, blurred vision, or urinary retention.

Q: Is Novagest with Codeine used to treat chronic or acute conditions?

A: Regulatory documents clearly specify that this medicine is strictly intended for short-term use only. It is generally utilized for the symptomatic relief of acute conditions, such as severe cough and cold symptoms that develop suddenly and do not last long.

Q: What are the signs that Novagest with Codeine might be causing a serious reaction?

A: Official safety information requires that patients be monitored for critical signs of serious reactions, especially respiratory depression. Key signs documented include experiencing profound sedation (extreme sleepiness) and having slowed or shallow breathing.

Q: Can Novagest with Codeine be taken with herbal supplements?

A: Official sources advise caution with herbal supplements, noting that some may interact with the Codeine component. The potential for adverse interactions has been documented with certain herbal products, such as St. John's wort, which may affect the metabolism of the Codeine component.

How should Novagest with Codeine be stored and disposed of?

How to Store and Dispose of Novagest with Codeine?

As a controlled substance containing Codeine, Novagest with Codeine Oral Solution is subject to specific regulatory requirements for storage and disposal to ensure stability and public safety.

Official Storage Requirements

Storage Component Requirement
Temperature Store at Controlled Room Temperature (20^circC to 25^circC).
Environment Protect from light, keep tightly closed, and Keep from freezing.
Child Safety Mandatory: Keep out of the sight and reach of children and pets.

Official Disposal Instructions

Unused or expired medicine must be disposed of promptly. The preferred method is to utilize an official drug take-back program or mail-back envelope. If a take-back option is not available, the alternative method is to mix the liquid with an unappealing substance (like dirt or used coffee grounds), seal the mixture in a bag, and place it in the household trash. The bottle's label should have all personal information scratched out before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Novagest with Codeine found in:

A-Z Index: